Probiotics to prevent or treat excessive infant crying: systematic review and meta-analysis

Valerie Sung1, Sarsha Collett, Tanyth de Gooyer

  • 1Department of Paediatrics, The University of Melbourne, Parkville, Australia2Murdoch Childrens Research Institute, Parkville, Australia3Centre for Community Child Health, Royal Children's Hospital, Parkville, Australia.

JAMA Pediatrics
|October 9, 2013
PubMed

Insights

Probiotics show limited effectiveness for infant colic. Lactobacillus reuteri may help breastfed infants, but more research is needed for formula-fed babies and prevention strategies.

Area of Science:

  • Pediatrics
  • Gastroenterology
  • Microbiology

Background:

  • Excessive infant crying, or colic, is a common and distressing issue for families.
  • Current prevention and management options for infant colic lack proven efficacy.
  • Probiotics are being explored as a potential therapeutic solution.

Purpose of the Study:

  • To systematically evaluate the effectiveness of probiotics in preventing or managing infant crying (colic) in infants aged 3 months or younger.

Main Methods:

  • A systematic literature search was conducted across major databases (MEDLINE, EMBASE, Cochrane Library).
  • Included studies were randomized controlled trials comparing probiotics to placebo or standard care.
  • Data were extracted and synthesized following Cochrane and PRISMA guidelines.

Main Results:

  • Six of twelve reviewed trials suggested probiotics reduced infant crying; six did not.
  • Meta-analysis of three trials indicated Lactobacillus reuteri significantly reduced crying time in breastfed infants with colic.
  • Evidence for effectiveness in formula-fed infants or for prevention of crying was insufficient, with considerable study variability.

Conclusions:

  • Lactobacillus reuteri may be effective for managing colic in exclusively breastfed infants.
  • Insufficient evidence currently supports probiotic use for managing colic in formula-fed infants or for colic prevention.
  • Larger, rigorously designed studies are needed to establish definitive conclusions on probiotic efficacy for infant crying.

Related Concept Videos

Development of Human Microbiota01:30

Development of Human Microbiota

The human microbiota begins developing at birth and undergoes continual change as we age. Infancy marks a critical period of microbial sensitivity, offering a “window of opportunity” during which beneficial microbes help mature the immune system. By age three, children typically develop a more stable and diverse microbial community. Newborns acquire microbes from their immediate environment; vaginal delivery favors maternal vaginal microbes, while cesarean births favor microbes from...
73
Probiotics01:22

Probiotics

Probiotics are live, non-pathogenic microorganisms that confer health benefits by modulating the gut microbiota. The human gastrointestinal tract harbors a complex microbial ecosystem, and the balance of this microbiota is crucial for digestive and systemic health. Among the most extensively studied and utilized probiotics are species formerly classified within the genera Lactobacillus and Bifidobacterium. These organisms not only naturally colonize the human gut but are also consumed through...
300
Development of the Oral Microbiota01:28

Development of the Oral Microbiota

The establishment of the oral microbiome begins before birth, challenging the long-held belief that the fetal oral cavity is sterile. The presence of oral microbes such as Streptococcus and Fusobacterium in amniotic fluid suggests that microbial exposure may occur in utero, potentially through translocation from the maternal oral or gastrointestinal tract. This early colonization primes the neonatal immune system and sets the stage for subsequent microbial succession. Maternal health,...
75
Gut-Brain Axis01:22

Gut-Brain Axis

The gut–brain axis is a bidirectional communication system that connects the gastrointestinal tract and the brain. This interaction is mediated through multiple pathways, including the vagus nerve, hormonal signals, immune responses, and chemical messengers produced by gut microbes.Microbial Contributions to Brain FunctionGut microbiota contributes significantly to brain function by producing neuroactive compounds. These include neuroactive compounds that influence neurotransmitters such...
252
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.5K